Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-3,671
Closed -$282K 238
2022
Q1
$282K Buy
+3,671
New +$264K 0.01% 192
2021
Q4
Sell
-12,281
Closed -$906K 460
2021
Q3
$906K Buy
+12,281
New +$921K 0.01% 337
2021
Q2
Sell
-4,580
Closed -$341K 760
2021
Q1
$341K Buy
4,580
+3,076
+205% +$234K ﹤0.01% 418
2020
Q4
$110K Sell
1,504
-11,851
-89% -$837K ﹤0.01% 580
2020
Q3
$888K Buy
13,355
+4,114
+45% +$260K 0.02% 313
2020
Q2
$527K Buy
9,241
+7,474
+423% +$367K 0.01% 437
2020
Q1
$62K Buy
+1,767
New +$84.1K ﹤0.01% 447
2017
Q4
Sell
-139,580
Closed -$5.12M 189
2017
Q3
$5.12M Buy
139,580
+51,070
+58% +$2.06M 0.07% 66
2017
Q2
$4.02M Buy
+88,510
New +$3.91M 0.05% 57

Other funds holding HOLX

Maverick Capital's HOLX Position: Q2 2022 in Review

Maverick Capital sold out of Hologic (HOLX) in Q2 2022, closing a stake of 3,671 shares — an estimated $282K sold.

Maverick Capital first reported a position in HOLX in Q2 2017 and held it in 9 quarters. The position peaked at $5.12M in Q3 2017. 694 funds tracked by Wall St. Rank hold HOLX as of Q2 2022.

  • Maverick Capital reported no remaining Hologic position as of Q2 2022 after selling out during the quarter.
  • Maverick Capital sold 3,671 Hologic shares in Q2 2022, an estimated $282K.
  • Maverick Capital first reported a position in Hologic in Q2 2017 and held it in 9 quarters.
  • Maverick Capital's Hologic position peaked at $5.12M in Q3 2017.
  • 694 funds tracked by Wall St. Rank held Hologic as of Q2 2022.

Based on Maverick Capital's 13F filing for Q2 2022, filed 15 Aug 2022.